PARP阻害剤:臨床における合成致死性
Christopher J Lord1, Alan Ashworth2
1The Cancer Research UK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. chris.lord@icr.ac.uk alan.ashworth@ucsf.edu.
Science (New York, N.Y.)
|March 18, 2017
まとめ
ポリ ((ADP-リボース) ポリメラーゼ阻害剤 (PARPi) は,BRCA変異がんにおける合成致死性を利用する. 研究は,PARPi耐性を克服し,より広範ながん治療のための組み合わせ療法を最適化することを探求しています.
科学分野:
- 腫瘍学
- 分子生物学
- 遺伝学
背景:
- PARP阻害剤 (PARPi) は新しいがん治療のクラスです.
- 彼らは,特にBRCA1/BRCA2変異の特定のDNA修復欠陥を持つ腫瘍を標的として,合成致死性の概念を活用しています.
- PARPiはBRCA変異以外のがんに有効性を示し,DNA修復の欠陥が類似している.
研究 の 目的:
- PARP阻害剤に関する現在の理解をレビューする.
- 臨床的効果を高めるための戦略を探求する.
- 耐性および最適な組み合わせのアプローチを含む,PARPi治療における課題について議論する.
主な方法:
- PARP阻害剤に関する臨床前および臨床研究のレビュー
- 癌遺伝学の合成致死性の原理の分析
- 薬剤耐性メカニズムと併用療法戦略の検討
主要な成果:
- PARPiは,合成による致死性により,BRCA変異がんに有効です.
- PARPiは,同種の再結合DNA修復欠陥を有する他の癌において有望である.
- PARPiに対する耐性は,進行した疾患において重要な課題です.
結論:
- PARPiの開発は他の標的型がん治療法にも 価値ある洞察をもたらします
- 耐性を克服し,組み合わせ治療を最適化するためにさらなる研究が必要です.
- PARPiの臨床効果を最大化するには,そのメカニズムと耐性経路の全面的な理解が必要です.
関連する概念動画
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:37Restarting Stalled Replication Forks
6.5K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.5K